Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta

BMC Infectious Diseases

Isabel C Scarinci²  Patti E Gravitt¹  Alfio Rausa³  Edward E Partridge²  Julia C Gage⁴  Philip E Castle⁵ 

[1] Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA;University of Alabama at Birmingham, Birmingham, AL, USA;Mississippi State Department of Health, Jackson, MS, USA;Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA;Global Cancer Imitative, Chestertown, MD, USA

关键词: Cervix;    Cervical intraepithelial neoplasia;    Pap;    Self-collection;    Human papillomavirus (HPV);   

Others  :  1158617
DOI  :  10.1186/1471-2334-13-5

 received in 2012-06-14, accepted in 2012-12-19,  发布年份 2013

【 摘 要 】

Background

There are no data available on human papillomavirus (HPV) infections in women living in the Mississippi Delta, where cervical cancer incidence and mortality among African American women is among the highest in the United States. The aim of this analysis was to report the age-specific prevalence of HPV in this population.

Methods

We recruited 443 women, 26–65 years of age, from the general population of women living in the Mississippi Delta to participate; 252 women had been screened for cervical cancer within the last 3 years while 191 had not. Women underwent a pelvic exam and had clinician-collected Pap sample taken for the routine cervical cancer screening by cytology. Women were asked to collect a self-collected specimen at home and return it to the clinic. Both specimens were tested for HPV genotypes.

Results

Four hundred and six women (91.6%) had HPV genotyping results for the clinician-collected and self-collected specimens. The prevalence of carcinogenic HPV was 18.0% (95% CI: 14.4%-22.1%) for clinician-collected specimens and 26.8% (95% CI: 22.6%-31.4%) for self-collected specimens. The concordance for the detection of carcinogenic HPV between clinician-collected and self-collected specimens was only fair (kappa = 0.54). While the prevalence of carcinogenic HPV in either sample decreased sharply with increasing age (p_trend< 0.01), the prevalence of non-carcinogenic HPV did not, especially the prevalence of HPV genotypes in the alpha 3/4/15 phylogenetic group.

Conclusions

The prevalence of carcinogenic HPV in our sample of women living in the Mississippi Delta was greater than the prevalence reported in several other U.S. studies. The high carriage of HPV infection, along with lack of participation in cervical cancer screening by some women, may contribute to the high cervical cancer burden in the region.

【 授权许可】

   
2013 Castle et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Schiffman M, Castle PE, Jeronimo J, et al.: Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
• [2]Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
• [3]Naucler P, Ryd W, Tornberg S, et al.: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
• [4]Mayrand MH, Duarte-Franco E, Rodrigues I, et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
• [5]Cuzick J, Clavel C, Petry KU, et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
• [6]Zhao FH, Lewkowitz AK, Chen F, et al.: Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst 2012, 104:178-188.
• [7]Harper DM, Hildesheim A, Cobb JL, et al.: Collection devices for human papillomavirus. J Fam Pract 1999, 48:531-535.
• [8]Virtanen A, Nieminen P, Luostarinen T, et al.: Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011, 20:1960-1969.
• [9]Gok M, Heideman DA, van Kemenade FJ, et al.: HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010, 340:c1040.
• [10]Gok M, Heideman DA, van Kemenade FJ, et al.: Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders. Eur J Cancer 2012, 48:1799-1808.
• [11]Szarewski A, Cadman L, Mesher D, et al.: HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer 2011, 104:915-920.
• [12]Lindell M, Sanner K, Wikstrom I, et al.: Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG 2012, 119:245-248.
• [13]Harper DM, Longacre MR, Noll WW, et al.: Factors affecting the detection rate of human papillomavirus. Ann Fam Med 2003, 1:221-227.
• [14]Harper DM, Noll WW, Belloni DR, et al.: Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed–biologic concordance and women’s preferences. Am J Obstet Gynecol 2002, 186:365-373.
• [15]Harper DM, Raymond M, Noll WW, et al.: Tampon samplings with longer cervicovaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk human papillomavirus. Sex Transm Dis 2002, 29:628-636.
• [16]Freeman HP, Wingrove BK: Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005. NIH Pub. No. 05–5282
• [17]Scarinci IC, Garcia FA, Kobetz E, et al.: Cervical cancer prevention: new tools and old barriers. Cancer 2010, 116:2531-2542.
• [18]Castle PE, Rausa A, Walls T, et al.: Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med 2011, 52:452-455.
• [19]Gage JC, Partridge EE, Rausa A, et al.: Comparative performance of human papillomavirus DNA testing using novel sample collection methods. J Clin Microbiol 2011, 49:4185-4189.
• [20]Castle PE, Aftab A, Saint-Jean G, et al.: Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device. J Clin Microbiol 2006, 44:2158-2159.
• [21]Kobetz E, Kish JK, Campos NG, et al.: Burden of Human Papillomavirus among Haitian Immigrants in Miami, Florida: Community-Based Participatory Research in Action. J Oncol 2012, 2012:728397. Epub;%2012 Mar 15.:728397
• [22]Castle PE, Sadorra M, Garcia FA, et al.: Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens. Cancer Epidemiol Biomarkers Prev 2007, 16:840-843.
• [23]Castle PE, Gravitt PE, Solomon D, et al.: Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008, 46:109-117.
• [24]Gravitt PE, Schiffman M, Solomon D, et al.: A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008, 17:1248-1254.
• [25]Bouvard V, Baan R, Straif K, et al.: A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009, 10:321-322.
• [26]Schiffman M, Herrero R, Desalle R, et al.: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 20(337):76-84.
• [27]Bernard HU, Burk RD, Chen Z, et al.: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
• [28]Castle PE, Schiffman M, Bratti MC, et al.: A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004, 190:458-467.
• [29]Castle PE, Rodriguez AC, Porras C, et al.: A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007, 34:849-855.
• [30]Castle PE, Jeronimo J, Schiffman M, et al.: Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res 2006, 66:1218-1224.
• [31]Castle PE, Schiffman M, Glass AG, et al.: Human papillomavirus prevalence in women who have and have not undergone hysterectomies. J Infect Dis 2006, 194:1702-1705.
• [32]Saslow D, Solomon D, Lawson HW, et al.: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012, 62:147-172.
• [33]Saslow D, Solomon D, Lawson HW, et al.: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J Low Genit Tract Dis 2012, 16:175-204.
• [34]Moyer VA: Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012, 156:880-891.
• [35]Castle PE, Fetterman B, Poitras N, et al.: Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. Obstet Gynecol 2009, 113:595-600.
• [36]Datta SD, Koutsky LA, Ratelle S, et al.: Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med 2008, 148:493-500.
• [37]Wheeler CM, Hunt WC, Cuzick J, et al.: A Population-based study of HPV genotype prevalence in the United States: Baseline measures prior to mass HPV vaccination. Int J Cancer 2013, 132:198-207.
• [38]Maucort-Boulch D, Franceschi S, Plummer M: International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008, 17:717-720.
• [39]Wright TC Jr, Schiffman M: Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003, 348:489-490.
• [40]Castle PE, Porras C, Quint WG, et al.: Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol 2008, 46:3437-3445.
• [41]Stevens MP, Garland SM, Rudland E, et al.: Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007, 45:2130-2137.
• [42]Castle PE, Sadorra M, Lau T, et al.: Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol 2009, 47:3344-3347.
• [43]Garcia-Closas M, Egan KM, Abruzzo J, et al.: Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001, 10:687-696.
• [44]Hariri S, Unger ER, Sternberg M, et al.: Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infect Dis 2011, 204:566-573.